Fernando Aranda

12PUBLICATIONS
29CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosisGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 24, 2025
The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosis.

Celia Gomar, Aline Risson, Leire Arrizabalaga

|Apr 17, 2024
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C.

Celia Gomar, Claudia Augusta Di Trani, Angela Bella

|Dec 21, 2023
The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis.

Ángela Bella, Ignacio Melero, Pedro Berraondo

|Nov 02, 2023
Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis.

Ángela Bella, Leire Arrizabalaga, Claudia Augusta Di Trani

|Dec 19, 2022
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8+ T cells eradicates peritoneal metastases in mouse models.

Claudia Augusta Di Trani, Assunta Cirella, Leire Arrizabalaga

|Jul 21, 2022
Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis.

Ángela Bella, Leire Arrizabalaga, Claudia Augusta Di Trani

Pageof 2

Frequent Collaborators

6 joint publications

Pedro Berraondo

4 joint publications

Ignacio Melero

2 joint publications

Myriam Fernandez-Sendin

2 joint publications

Nuria Ardaiz